Table 2.
Univariate analysis and multivariate analysis of prognostic factors associated with OS
| Variables | Univariate Analysis | Multivariate Analysis | ||
|---|---|---|---|---|
|
|
|
|||
| HR (95% CI) | P | HR (95% CI) | P | |
| Age > 60 | 0.86 (0.60-1.49) | 0.591 | ||
| Sex female | 1.46 (0.80-2.67) | 0.217 | ||
| Body mass index > Median (22.2) | 0.8 (0.47-1.41) | 0.461 | ||
| Serum albumin ≤ 35 g/L | 2.85 (1.55-5.26) | 0.001 | 2.29 (1.18-4.47) | 0.015 |
| Serum CA-199 (U/ml) > 37 | 0.97 (0.52-1.80) | 0.912 | ||
| Serum CEA (ng/ml) > 5 | 1.45 (0.83-2.51) | 0.188 | ||
| ASA score 3-4 | 1.59 (0.70-3.61) | 0.265 | ||
| Child-Pugh B | 0.84 (0.42-1.68) | 0.623 | ||
| Liver cirrhosis | 1.28 (0.65-2.49) | 0.475 | ||
| Tumor size > 5 cm | 1.82 (1.04-3.20) | 0.035 | ||
| Multiple tumors | 1.06 (0.55-2.03) | 0.865 | ||
| Poor differentiation | 3.24 (1.81-5.83) | < 0.001 | ||
| Lymphonodus metastasis | 5.91 (2.78-12.59) | < 0.001 | ||
| TNM stage III+IV | 10.33 (4.73-22.60) | < 0.001 | 7.94 (3.54-17.81) | < 0.001 |
| Clavien grade ≥ 3 | 0.82 (0.39-1.75) | 0.609 | ||
| Sarcopenia | 3.40 (1.91-6.03) | < 0.001 | 3.01 (1.65-5.51) | < 0.001 |
CA19-9 carbohydrate antigen 19-9; CEA carcino-embryonic antigen; ASA score American Society of Anaesthesiologists score; TNM tumor-node-metastasis; HR hazard ratio; CI confidential interval; Variables in bold are statistically significant in multivariate analysis (P < 0.05).